Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6702997	MYLAN SPECIALITY LP	Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma	Dec, 2021 (2 years ago)

Accuneb is owned by Mylan Speciality Lp.

Accuneb contains Albuterol Sulfate.

Accuneb has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Accuneb are:

Accuneb was authorised for market use on 30 April, 2001.

Accuneb is available in solution;inhalation dosage forms.

Accuneb can be used as indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease).

The generics of Accuneb are possible to be released after 28 December, 2021.

Market Authorisation Date: 30 April, 2001

Treatment: Indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease)

Dosage: SOLUTION;INHALATION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00021	19 Oct, 2005	1	25 Sep, 2007	28 Dec, 2021	Eligible
0.00042	06 Apr, 2004	1	28 Jun, 2004	28 Dec, 2021	Eligible

Strength	Dosage	Availability
EQ 0.021% BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;INHALATION	Discontinued
EQ 0.042% BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION;INHALATION	Discontinued

Accuneb patents expiration